23 slides from Aiforia Technologies Oy Class A's earnings presentation, Mar 6, 2026
Slide 1: Aiforia - AI for image analysis
. @ aifor Al for image analysis
Slide 2: Clinical sector revenue increased 68% in 2025, driven by portfolio expansion and commercial execution
Clinical sector revenue increased 68% in 2025, driven by portfolio expansion and commercial execution Financial Statements Bulletin 2025 for January 1 - December 31, 2025 Aiforia Technologies Plc March 6, 2026
Slide 3: Today's agenda
Today’s agenda 01. Highlights of the second half and FY of 2025 02. Strategy execution 03. Q&A Jukka Tapaninen CEO March 6, 2026 | Financial Statements Bulletin, January 1–December 31, 2025 3
Slide 4: H2 & FY 2025 highlights
H2 & FY 2025 highlights Strong progress on clinical customer deployments - clinical sector revenue increased +68% (FY 2025), driven by portfolio expansion and commercial execution. Growth supported by increasing number of partnerships including strategic partnership with Siemens Healthineers. IVDR c
Slide 5: Recent clinical deals and collaborations
Recent clinical deals and collaborations Mayo Clinic Institut Curie, France ● Breast and prostate cancer diagnostics ● Breast cancer diagnostics in routine use since 2023. ● +70 pathologists using Aiforia® Platform in translational research Nantes University Hospital, France ● Prostate cancer diagno
Slide 6: Investments in product development continued
Investments in product development continued ● Aiforia continued investing in product development. Gross investments in FY 2025 amounted to EUR 6.6 million (5.7). Key development highlights: ● Clinical Diagnostics: Developed new AI models and user interfaces for more efficient case-level review and r
Slide 7: Aiforia secured IVDR certificates for the first products in February 2025
Aiforia secured IVDR certificates for the first products in February 2025 The certificates confirm that Aiforia's clinical solutions meet stringent safety, performance, and risk management requirements according to the EU IVD Regulation, and enable Aiforia to introduce a broader range of products to the
Slide 8: FY 2025 results in brief
FY 2025 results in brief 18% Group revenue increased by +24% to EUR 6,645 (5,652) thousand investment mainly in EUR 3,535 (2,852) thousand, clinical sector product development revenue increased by +68% EBITDA improved to EUR -6,045 (-8,220) thousand Finland EBIT improved to EUR –11,183 (-12,195) tho
Slide 9: 2025: Revenue improved
2025: Revenue improved Revenue full year Revenue H2 EUR, thousand +24% EUR, thousand 4,000 3.535 +45% 3,000 2.852 3,000 +68% 2.140 2.307 1.377 2,000 2,000 1.479 +65% 1.509 1,000 0.912 1,000 1.475 1.228 0.567 0.631 0 0 2024 2025 H2/2024 H2/2025 Clinical Non-clinical Clinical Non-clinical Revenue cons
Slide 10: Strategy execution
aiforia 2 Strategy execution
Slide 11: Market opportunity
Market opportunity Population in relation to the number of … with no reduction of sample Pathologists Per Million pathologists¹ volumes in sight Estimated global cancer increases cases 2020-20404 Rising rates of disease like cancer, .. 2.0% CAGR 30% increase in cancer 28.9 m rates in the US in past
Slide 12: Adoption of AI in pathology is accelerating
Adoption of AI in pathology is accelerating AI-supported diagnosis Microscope Report for the clinician Tissue sample Scanner Image upload treating the patient Use of AI Any type of biological Majority of scanner Image is transferred to Benefits and result: sample or staining is and file formats are PA
Slide 13: Key competitive advantages
Key competitive advantages AI TECHNOLOGY LEADERSHIP ● Pioneer in providing commercial AI training tools for pathologists since 2018 ● Aiforia platform enables development of both diagnostic and predictive AI models ● Continuous product development to leverage new technologies, such as foundation mod
Slide 14: Aiforia Clinical Suites
Aiforia® Aiforia® Lung Cancer Suite: PD-L1* Clinical Suites Aiforia® Lymph Node Metastasis* Integrated AI pathology – fast, precise, proven Aiforia® Breast Cancer Suite: ER*, PR*, Ki67*, HER2*, Grading* ● Increased efficiency ● Advanced precision Aiforia® Gastric Suite Aiforia® Colon Suite: Gastric C
Slide 15: Expected benefits for the patients
Expected benefits for the patients Through AI-driven diagnostics Aiforia aims to enable better care for each patient ● Faster care path: Accelerated diagnosis may reduce patient waiting times, allowing treatment to begin sooner. ● Personalized treatment: Improved diagnostic accuracy enables more prec
Slide 16: Aiforia provides solutions for up to ~60% of histopathology samples
Aiforia provides solutions for up to ~60% of histopathology samples with current and pipeline modules, and >80% by 2030 DIRECTIONAL Aiforia Presence 2026 Growth by 2030 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Gastrointestinal Breast GU (Prostate) Lung Lymphoid Key: Dermatopathology Gynecologic H
Slide 17: Short and longer-term growth drivers enable continued maximization of opportunity
Short and longer-term growth drivers enable continued maximization of opportunity as the market matures Longer-term Growth Drivers 2030+ Short-term Growth Drivers To 2030 Global Prognostic Pharma: Maximize Grow Elevate User Markets: Applications: Partner to Opportunity Clinical Experience: Capitaliz
Slide 18: Mid-term business targets
Mid-term business targets Achieve financial independence by the end of 2027 Create a product offering that covers 80% of the pathologist’s diagnostic workflow (2030) Achieve 50 key accounts (potential for over 500 EUR thousand in annual recurring revenue) (2030) Leverage technology beyond diagnostic s
Slide 19: Q&A
3 Q&A 19
Slide 20: Forthcoming events
Forthcoming events March 11, 2026 April 2 , 2026 August 28, 2026 The Board of Directors’ Report Half-Year Financial Report and the Financial Statements Annual General Meeting 2025 for January 1 – June 30, 2026 for financial year 2025 will be Materials are available at will be published published http
Slide 21: For more information
For more Investor Relations Contacts information Jukka Tapaninen, CEO jukka.tapaninen@aiforia.com, +33 61 041 6686 www. investors.aiforia.com ir@aiforia.com
Slide 22: Disclaimer
Disclaimer It should be noted that Aiforia and its business are exposed to various risks and uncertainties, and certain statements herein which are not historical facts, including without limitation, those regarding expectations for market growth and developments; expectations for growth and profitab
Slide 23: Aiforia - AI for image analysis
. @ aifor Al for image analysis 23